On April 28, 2017 Alligator’s reported that lead programme, ADC-1013, which has a pre-clinical profile indicating good safety and applicability in multiple tumor types, is currently being investigated in a second Phase I dose escalation trial (Press release, Alligator Bioscience, APR 28, 2017, View Source [SID1234538689]). The immuno-oncology antibody was out-licensed in August 2015 to Janssen Biotech Inc., an oncology company within the Johnson & Johnson group.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alligator’s wholly-owned product ATOR-1015 is a bispecific immuno-oncology compound that has the potential to be a first in class dual immune activating antibody.
"We are excited to be presenting these early data which provide further validation of the strength of our pipeline of tumor-directed immuno-oncology antibodies", says Per Norlén, Chief Executive Officer of Alligator Bioscience. "Alligator is deeply rooted in immuno-oncology and, as one of the first entrants into the scientific area in 2008, has successfully built a pipeline with the potential to provide much-needed treatments to patients suffering from multiple metastasizing cancers."
For further information, please contact:
Per Norlén, CEO
Telephone: + 46 46 286 42 80 (switchboard)
E-mail: [email protected]
Rein Piir, VP Investor Relations at Alligator
Telephone: +46 708 537292
E-mail: [email protected]
Per-Olof Schrewelius, CFO
Telephone: +46 46 286 42 85
E-mail: [email protected]
The information in the press release was submitted for publication at 1 p.m. CET on 28 April, 2017.